A phase II study of dasatinib in relapsed and-refractory chronic lymphocytic leukemia (CLL/SLL)

被引：6
|
作者：
Amrein, Philip C. [1 ]
Attar, Eyal C. [1 ]
Takvorian, Tak [1 ]
Hochberg, Ephraim P. [1 ]
Ballen, Karen [1 ]
Zabrieh, David [2 ]
Brown, Jennifer R. [2 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Dana Farber Canc Inst, Boston, MA USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.3126.3126
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3126
引用
收藏
页码：920A / 920A
页数：1
相关论文
共 50 条
  • [21] First Interim Analysis Of ALPINE Study: Results Of A Phase 3 Randomized Study Of Zanubrutinib Vs Ibrutinib In Patients With Relapsed / Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL / SLL)
    Hillmen, Peter
    Eichhorst, Barbara
    Brown, Jennifer R.
    Lamanna, Nicole
    O'brien, Susan
    Tam, Constantine S.
    Qiu, Lugui
    Kazmierczak, Maciej
    Zhou, Keshu
    Simkovic, Martin
    Mayer, Jiri
    Gillespie-Twardy, Amanda
    Shadman, Mazyar
    Ferrajoli, Alessandra
    Ganly, Peter S.
    Weinkove, Robert
    Salmi, Tommi
    Ji, Meng
    Yecies, Jessica
    Wu, Kenneth
    Novotny, William
    Huang, Jane
    Jurczak, Wojciech
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 143 - 144
  • [22] Efficacy and Safety Results of TQB3909 in Patients (Pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Zhou, Keshu
    Xing, Hongyun
    Teng, Qingliang
    Li, Wuping
    Wang, Yafei
    Zhu, Feng
    Jin, Zhengming
    Zhiming, Li
    Ouyang, Guifang
    Xu, Fang
    Huang, Shihua
    Li, Jianyong
    BLOOD, 2024, 144 : 4628 - 4628
  • [23] Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Badoux, Xavier C.
    Keating, Michael J.
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Estrov, Zeev
    Pasia, Manolo
    Lerner, Susan
    Sargent, Rachel L.
    Kantarjian, Hagop M.
    Ferrajoli, Alessandra
    BLOOD, 2011, 118 (21) : 448 - 448
  • [24] A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Barr, Paul M.
    Hill, Brian T.
    Ma, Shuo
    Baran, Andrea M.
    Bui, Andrew
    Meacham, Philip J.
    Morrison, Ashley
    Liesveld, Jane L.
    Mulford, Deborah A.
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Friedberg, Jonathan W.
    Zent, Clive S.
    BLOOD, 2019, 134
  • [25] A phase II study of induction followed by intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Shouse, Geoffrey
    Chen, Lu
    Siddiqi, Tanya
    Muir, Alex
    Brown, Jennifer R.
    Spurgeon, Stephen E.
    Danilov, Alexey V.
    LEUKEMIA & LYMPHOMA, 2024, 65 (10) : 1516 - 1519
  • [26] DASATINIB PLUS FLUDARABINE IN PATIENTS WITH REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A MULTICENTER PHASE II STUDY
    Kater, A.
    Spiering, M.
    Lui, R.
    Beckers, M.
    Tonino, S.
    Doorduijn, J.
    Daenen, S.
    Luijks, D.
    Eldering, E.
    van Oers, M.
    HAEMATOLOGICA, 2012, 97 : 304 - 304
  • [27] ACADESINE FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MULTICENTRE PHASE I/II STUDY
    van den Neste, E.
    Janssens, A.
    Gonzalez-Barca, E.
    Cazin, B.
    Terol, M. J.
    Levy, V.
    Perez de Oteyza, J.
    Saunders, A.
    De Elias, M.
    Campas, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 325 - 325
  • [28] Pirtobrutinib in Relapsed or Refractory CLL and SLL
    Woyach, Jennifer A.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (05) : 230 - 231
  • [29] A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL
    Crombie, Jennifer L.
    Tyekucheva, Svitlana
    Savell, Alexandra
    Francoeur, Karen
    Choiniere, Mark
    Montegaard, Josie
    Soumerai, Jacob D.
    Arnason, Jon E.
    Fisher, David C.
    Brown, Jennifer R.
    Davids, Matthew S.
    BLOOD, 2019, 134
  • [30] Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study
    Jones, Jeffrey Alan
    Geyer, Susan
    Andritsos, Leslie A.
    Awan, Farrukh
    Flynn, Joseph M.
    Maddocks, Kami J.
    Bingman, Anissa
    Johnson, Amy J.
    Heerema, Nyla A.
    Brookfield, Cathy
    Byrd, John C.
    Grever, Michael R.
    BLOOD, 2014, 124 (21)
12345